Abstract
Polycystic ovary syndrome (PCOS) is characterized by anovulation, hyper-androgenism and polycystic ovaries on scanning and is the most common endocrine disorder in women of reproductive age. Testo, is an Ayurvedic poly-herbal preparation has been used by physician for infertility and menstrual irregularity since centuries. To assess the effect of Testo as the first-line medication to be used in anovulatory cycles in patients with PCOS for ovulation induction. We conducted a case series on 11 females of PCOS with anovulatory cycles. After informed consent, patients were treated with Testo, one capsule twice daily. Outcomes were based on serum progesterone test at day 22nd of each treatment cycle, ultrasonography finding of ovulation and effect on menstrual cycle irregularity. We observed, the rate of ovulation in 1st treatment cycle was 45.45% while in 2nd treatment cycle, the rate of ovulation was highly significant 81.81% without any adverse effects. Menstrual cycle got regulated in all the patients along with relief in dysmenorrhea. The rate of ovulation observed with Testo treatment in second cycle of treatment, was 81.81% while with clomiphene citrate [CC], ovulation rate was 59 % and with combination therapy (metformin + clomiphene citrate), was 68% in a clinical trial, revealing potential of Testo in ovulation over CC and metformin. We reviewed the literature related to the Testo, its constituents, have exhibited potential folliculogenetic, estrogenic, progesteronic, anti-inflammatory, analgetic, astringent activities, suggesting plausible mechanisms of action in these patients. The preliminary findings indicate the safe and potential ovulation inducing role of Testo. Further trials is undergoing, which is aimed to explore the therapeutic potential of this medicine in anovulatory infertility.
